Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFueyo, J.en
dc.contributor.authorGomez-Manzano, C.en
dc.contributor.authorPuduvalli, V. K.en
dc.contributor.authorMartin-Duque, P.en
dc.contributor.authorPerez-Soler, R.en
dc.contributor.authorLevin, V. A.en
dc.contributor.authorYung, W. K.en
dc.contributor.authorKyritsis, A. P.en
dc.rightsDefault Licence-
dc.subjectAntineoplastic Agents/therapeutic use/toxicityen
dc.subjectCell Cycle/drug effectsen
dc.subjectCell Division/drug effectsen
dc.subjectCyclin-Dependent Kinase Inhibitor p16/biosynthesis/*metabolismen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDrug Resistance, Neoplasmen
dc.subjectG1 Phaseen
dc.subjectGlioma/*drug therapyen
dc.subjectPaclitaxel/therapeutic use/*toxicityen
dc.subjectRecombinant Proteins/biosynthesisen
dc.subjectTime Factorsen
dc.subjectTopotecan/therapeutic use/*toxicityen
dc.titleAdenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapyen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractMalignant gliomas are highly resistant to chemotherapy, in part because of the blood-brain barrier, which restricts the delivery of chemotherapy to certain areas of tumor and their cellular heterogeneity, which leads to the selection and propagation of resistant clones. However, the molecular basis of the drug resistance is poorly understood. In this study, we examined the effect of the cell cycle-inhibitory protein p16 on the chemosensitivity of human glioma cells. Treatment of the p16-null glioma cells, U-251 MG and D-54 MG, with paclitaxel and topotecan, resulted in cell death within 4 days. However, overexpression of exogenous wild-type p16 protein using an adenovirus vector resulted in G1 arrest of glioma cells and resistance to the anticancer effect of paclitaxel or topotecan. Specifically, the p16-expressing cells showed a 30-fold increase in the ID50 of topotecan and a more than 40-fold increase in the ID50 of paclitaxel. These observations indicate that overexpression of molecules that control cell-cycle progression may be partially responsible for causing the resistance of glioma cells to cytocidal drugs.en
heal.journalNameInt J Oncolen
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.

This item is licensed under a Creative Commons License Creative Commons